Why Myopia Management Matters
Myopia is not simply a need for glasses, it is a progressive structural change in the eye. As the eye elongates (axial elongation), the retina becomes increasingly stretched and vulnerable. Higher levels of myopia are associated with significantly elevated lifetime risk of retinal detachment, myopic maculopathy, glaucoma, and other sight-threatening complications.
Recent global data show that earlier onset of myopia increases the likelihood of developing high myopia in adulthood. Since axial growth occurs most rapidly in childhood, intervention during this window can meaningfully reduce cumulative long-term risk. Myopia management is therefore preventive medicine. The goal is not just clearer vision today but reducing structural risk decades from now.
What Causes Myopia Progression
Current research supports a multifactorial model. Myopia progression is influenced by:
- Genetics (parental myopia significantly increases risk)
- Environmental exposure (limited outdoor time, high near demand)
- Age of onset (younger onset correlates with faster progression)
- Peripheral retinal defocus signaling, which appears to regulate ocular growth
Over the past several years, strong evidence has reinforced the role of peripheral retinal defocus in stimulating axial elongation. This understanding directly informs modern treatment design, specifically the optical strategies that alter peripheral focus to slow eye growth.
In simple terms: the eye grows in response to visual signals. Myopia management works by modifying those signals.
What Treatments Are Clinically Proven
High-quality randomized clinical trials and updated 2024–2025 meta-analyses consistently show that the following treatments reduce axial elongation compared to single-vision correction:
Orthokeratology (Overnight Corneal Reshaping Lenses)
- Reduces axial elongation by approximately 35–60%
- Works by reshaping the cornea and creating peripheral myopic defocus
- Requires careful hygiene and monitoring
Dual-Focus / Multifocal Soft Contact Lenses
- Demonstrated sustained slowing of axial growth in multi-year studies
- Treatment effect maintained with long-term wear
- FDA-approved options available
Peripheral Defocus / Lenslet Spectacle Designs
- Designed with concentric or segmental defocus elements
- Show meaningful reduction in both refractive progression and axial elongation
- Excellent option for younger children or those not ready for contacts
Low-Dose Atropine (0.025%–0.05%)
- Concentration-dependent effect
- Stronger efficacy at 0.05% compared to 0.01%
- Minimal side effects at modern dosing levels
Emerging evidence also supports combination therapy (for example, optical treatment plus low-dose atropine) in faster progressors, though individualized risk assessment is essential.
When should Myopia Management Begin?
Earlier treatment initiation is associated with greater cumulative lifetime benefit. Children under age 10 typically experience faster annual progression compared to teenagers. Waiting until myopia “gets worse” allows additional axial elongation that cannot be reversed.
Ideal candidates include:
- Newly diagnosed myopes under age 12
- Children progressing ≥0.50D per year
- Children with two myopic parents
- Early onset (before age 8–9)
Starting early does not “lock” a child into treatment forever, it reduces long-term structural risk during the years when progression is most aggressive.
Is Myopia Management Safe?
Contemporary safety data are reassuring when treatment is properly prescribed and monitored.
- Contact lens–based treatments demonstrate low complication rates with appropriate hygiene and follow-up schedules.
- Low-dose atropine at current concentrations has minimal systemic absorption and mild ocular side effects.
- Spectacle-based options carry no increased medical risk.
The key determinant of safety is structured follow-up and adherence to evidence-based protocols.
When managed by an experienced eye care professional, myopia control therapies demonstrate favorable safety profiles across large pediatric cohorts.
Takeaway for Parents
Myopia management is about proactive, it will help slow abnormal eye growth, reduce long-term retinal risk and gives families tools to protect vision for life. Certain types of Myopia management treatment, such as orthokeratology, can free a child from using glasses or contact lenses during the daytime. The earlier we intervene, the better the long-term outcome will be!
Please do not hesitate to contact me if you have any further questions or would like to schedule an appointment for a Myopia management evaluation.
Bullimore MA, et al. IMI—Interventions for Controlling Myopia Onset and Progression: Evidence Update Through 2024. Investigative Ophthalmology & Visual Science. 2025.
Xu H, et al. Orthokeratology vs Low-Dose Atropine for Myopia Control: A Randomized Clinical Trial. JAMA Ophthalmology. 2025.
Zhou Y, et al. Orthokeratology Lens Design and Myopia Control Efficacy: Updated Meta-Analysis. Eye & Contact Lens. 2024.
Chamberlain P, et al. Long-Term Outcomes of Dual-Focus Soft Contact Lenses for Myopia Control. Optometry and Vision Science. 2025.
Bao J, et al. Clinical Performance of Defocus Incorporated Multiple Segment Spectacle Lenses: Extended Follow-Up Results. British Journal of Ophthalmology. 2024.
Yam JC, et al. Updated Outcomes of Low-Concentration Atropine for Myopia Progression: Five-Year Clinical Data. Ophthalmology. 2024.
International Myopia Institute. IMI Clinical Management Guidelines Update. 2024 Consensus Report.
